6. A pharmaceutical composition comprising the crystal form obtained from the process of any of claims 1 to 5 and one or more carriers, excipients or diluents.

7. A use of the crystal form obtained from the process of any of claims 1 to 5 in the manufacture of a medicament for treating or preventing a disease or disorder associated with a premature stop codon in a patient in need thereof.

8. The use of claim 7 wherein the disease or disorder associated with a premature stop codon is multiple endocrine neoplasia (type 1, 2 and 3), amyloidosis, mucopolysaccharidosis (type I and III), congenital adrenal hypoplasia, adenomatous poliposis coli, Von Hippel Landau Disease, Menkes Syndrome, hemophilia A, hemophilia B, collagen VII, Alagille Syndrome, Townes-Brocks Syndrome, rhabdoid tumor, epidermolysis bullosa, Hurler's Syndrome, Coffin-Lowry Syndrome, aniridia, Charcot-Maria-Tooth Disease, myotubular myopathy, X-linked myotubular myopathy, X-linked chondrodysplasia, X-linked agammaglobulinemia, polycystic kidney disease, spinal muscular atrophy, familial adenomatous poliposis, pyruvate dehydrogenase deficiency, phenylketonuria, neurofibromatosis 1, neurofibromatosis 2, Alzheimer's disease, Tay Sachs disease, Rett Syndrome, Hermansky-Pudlak Syndrome, ectodermal dysplasia/skin fragility syndrome, Lori-Weill dyschondrosteosis, rickets, hypophosphataemic, adrenoleukodystrophy, gyrate atrophy, atherosclerosis, sensorineural deafness, dystonia, Dent Disease, acute intermittent porphyria, Cowden Disease, Herlitz epidermolysis bullosa, Wilson Disease, Treacher-Collins Syndrome, pyruvate kinase deficiency, giantism, dwarfism, hypothyroidism, hyperthyroidism, aging, obesity, Parkinson's disease, Niemann Pick's disease C, Cystic Fibrosis, muscular dystrophy, heart disease, kidney stones, ataxia-telangiectasia, familial hypercholesterolemia, retinitis pigmentosa, lysosomal storage disease, tuberous sclerosis, Duchenne Muscular Dystrophy, or Marfan Syndrome.

9. The use of claim 7 wherein the disease or disorder associated with a premature stop codon is a lysosomal storage disease, a cardiovascular disease, a pulmonary disease, heart disease, an autoimmune disease, a blood disease, a collagen disease, a polycystic kidney disease, retinitis pigmentosa, amyloidosis, aging, obesity, giantism, dwarfism, hypothyroidism, hyperthyroidism, diabetes, an inflammatory disease, a central nervous system disease, a muscular dystrophy or cancer.

10. The use of claim 9 wherein the cancer is selected from the group consisting of head, neck, eye, skin, mouth, throat, esophagus, chest, bone, lung, colon, sigmoid, rectum, stomach, prostate, breast, ovaries, kidney, liver, pancreas, brain, intestine, heart and

adrenals, or wherein the cancer is a solid tumor selected from the group consisting of a sarcoma, carcinoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, Kaposi's sarcoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, retinoblastoma, a blood-born tumor, acute lymphoblastic leukemia, acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute monoblastic leukemia, acute erythroleukemic leukemia, acute megakaryoblastic leukemia, acute myelomonocytic leukemia, acute nonlymphocytic leukemia, acute undifferentiated leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, and multiple myeloma.

11. The use of claim 10 wherein the cancer is associated with a premature stop codon in a tumor suppressor gene, wherein the tumor suppressor gene is selected from APC, ATM, BRCA1, BRCA2, MSH1, pTEN, Rb or p53.

12. The use of claim 10 wherein the autoimmune disease is rheumatoid arthritis or graft versus host disease; the blood disease is selected from the group consisting of a hemophilia A, hemophilia B, Von Willebrand disease, ataxia-telangiectasia, b-thalassemia and kidney stones; the collagen disease is Marfan syndrome, or osteogenesis imperfecta or cirrhosis; the lysosomal storage disease is tuberous sclerosis, or mucopolysaccharidosis type I, or mucopolysaccharidosis type III or Niemann Pick's disease; the inflammatory disease is arthritis; the central nervous system disease is selected from the group consisting of multiple sclerosis, late infantile neuronal ceroid lipofuscinosis, Alzheimer's disease, Tay Sachs disease, a neurodegenerative disease and Parkinson's disease; the cardiovascular disease is familial hypercholesterolemia or atherosclerosis; the pulmonary disease is cystic fibrosis; and the muscular dystrophy is Duchenne muscular dystrophy.